PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

BPC-157: Evidence Summary

Evidence summary for BPC-157 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.

Back to BPC-157 overview
Indication Evidence Tier Trial Count Summary
Musculoskeletal healing Tier C 0 Extensive animal data, no human RCTs
Gut healing Tier C 0 Strong preclinical GI protection data
Tendon repair Tier C 0 Animal models show accelerated healing

References (8)

  1. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM . Orthopaedic Journal of Sports Medicine (2025) PMID: 40756949
  2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review — Józwiak M, et al. . Pharmaceuticals (2025) DOI: 10.3390/ph18020185
  3. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway — Hsieh MJ, Liu HT, Wang CN, et al. . Scientific Reports (2020) PMID: 33051481
  4. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications — Sikiric P, et al. . Current Neuropharmacology (2018) PMID: 27138887
  5. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Gwyer D, Wragg NM, Wilson SL . Cell and Tissue Research (2019) PMID: 30915550
  6. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157 — Seiwerth S, et al. . Current Pharmaceutical Design (2012) PMID: 22950504
  7. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — Multiple authors . Clinical Pharmacology (2025) PMID: 40131143
  8. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress — Sikiric P, et al. . Digestive Diseases and Sciences (1997) PMID: 9073154